Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Trial Profile

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Etoposide-toniribate (Primary)
  • Indications Biliary cancer; Carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PIITCAP
  • Sponsors CellAct Pharma
  • Most Recent Events

    • 22 Feb 2019 Results presented in an Imbrium Therapeutics media release.
    • 22 Feb 2019 According to an Imbrium Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to etoposide toniribate, for the treatment of relapsed refractory biliary tract cancer. Encouraging data in Phase 2 trials were key in securing the ODD.
    • 19 Jan 2019 Results from biliary tract cancer patients (n=22) presented at the 2019 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top